Replies to post #6367 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Dasgrunt, that alone should push PPS north of $250.

I imagine if Cold Genesys announces positive results later this year they will be bought out by Pfizer. Especially with Luke Li on their BOD.

Luke Li - Managing Director, Ally Bridge Group

Luke has 30 years of experience in biopharma and healthcare business. Currently, he is a Managing Director at Ally Bridge Group (“ABG”), a global healthcare investment platform, where he oversees biopharma investment opportunities for the healthcare fund and plays an important role in guiding science and business development for ABG’s portfolio companies. Before joining ABG, Luke was an Executive Director and the Head of Global Biotherapeutics, External R&D Innovation at Pfizer from 2010 to 2015, where he led search and evaluation as well as business development for in-licensing of innovative assets and cutting-edge technologies. He focused on Oncology, Biotechnologies, Pharmaceutical Sciences as well as Biosimilars to strengthen Pfizer’s pipeline. Luke served as Amgen’s Executive Director from 1993 to 2009, leading discovery research to IND, in which he advanced more than 3 dozen biologics into development, including several marketed products. From 1986 to 1992, Luke completed his fellowship training in Hematology/Oncology, and then became an Assistant Professor in Medicine at Washington University Medical School. Luke earned his M.D. from Fujian Medical University.

Don't know what type of valuations you are looking at but ANIP's stake in Cold Genesys would create a bump in cash on hand and future royalties would add to cash flow.